# The RECOVER IV Trial

> **NCT05506449** · NA · TERMINATED · sponsor: **Abiomed Inc.** · enrollment: 4 (actual)

## Conditions studied

- ST-segment Elevation Myocardial Infarction (STEMI)
- Cardiogenic Shock

## Interventions

- **DEVICE:** Impella CP®
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT05506449
- **Lead sponsor:** Abiomed Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-10-28
- **Primary completion:** 2024-05-10
- **Final completion:** 2024-12-06
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Given the findings from the DanGer Shock RCT, the RECOVER IV independent DSMB believes that equipoise for randomization in the RECOVER IV Trial no longer exists and has recommended that the RECOVER IV Trial be permanently discontinued.
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05506449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05506449, "The RECOVER IV Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05506449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*